Printer Friendly

I-FLOW CORP. RECEIVES FDA PERMISSIONTO MARKET ITS PARAGON DRUG DELIVERY SYSTEM

 IRVINE, Calif., May 21 /PRNewswire/ -- I-FLOW Corp. (NASDAQ: IFLO), manufacturer and seller of innovative ambulatory infusion devices, today announced that the U.S. Food and Drug Administration (FDA) has granted the company permission to market the Paragon I.V. drug delivery system. This exciting new product gives the company the same technology leadership position for the I.V. delivery of critical drugs as the SideKick does in the antibiotic market. Domestic shipments of the Paragon are expected to begin in four to six weeks.
 The Paragon is the company's new low-cost IV drug delivery system for chemotherapy, pain medications and other life-saving drugs which need to be administered at very low flow rates over many days. It is highly accurate yet inexpensive to use and similar in design and concept to the SideKick. Because of its ability to maintain flow rate accuracy over long infusion periods (up to eight days), it will be marketed to home care providers and physicians as the low-cost alternative for delivering critical drugs. As with all I-FLOW products, the Paragon provides state-of-the-art technology which greatly reduces environmental risk and healthcare costs, while enhancing the patients' quality of life.
 I-FLOW Corp. designs, develops, manufactures and markets technically advanced ambulatory infusion systems uniquely well suited to the alternate care environment. Reliable, efficient and easy to use, I-FLOW products offer users substantial opportunities to expand their therapy base, improve quality of care and increase productivity. These advantages translate into improved revenues and profits for healthcare providers while reducing costs and improving the quality of life for patients.
 -0- 5/21/93
 /CONTACT: Jim Dal Porto, executive VP of I-FLOW, 714-553-0888/
 (IFLO)


CO: I-FLOW Corp. ST: California IN: MTC SU: PDT

JL-BP -- LA014 -- 1108 05/21/93 09:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 21, 1993
Words:291
Previous Article:CAPITAL CITY BANK GROUP REPORTS RESULTS
Next Article:NATIONAL COMPUTER SYSTEMS, INC. ANNOUNCES QUARTERLY CASH DIVIDEND
Topics:


Related Articles
I-FLOW CORP. RECEIVES FDA PERMISSION TO MARKET ITS NEW DISPOSABLE DRUG DELIVERY SYSTEM
I-FLOW CORP. FILES FOR FDA PERMISSION TO MARKET NEW DRUG DELIVERY SYSTEM
I-FLOW SIGNS NATIONAL DISTRIBUTION AGREEMENT FOR BOTH THE SIDEKICK AND THE PARAGON WITH SOLOPAK PHARMACEUTICALS INC.
I-FLOW SIGNS NATIONAL DISTRIBUTION AGREEMENT FOR BOTH THE SIDEKICK AND THE PARAGON WITH SOLOPAK PHARMACEUTICALS INC.
I-FLOW'S JAPANESE DISTRIBUTOR GAINS APPROVAL TO MARKET THE PARAGON
I-FLOW SIGNS LETTER OF INTENT WITH FRESENIUS FOR DISTRIBUTION IN GERMANY
I-FLOW RECEIVES NEW MEDICARE REIMBURSEMENT CODE FOR THE PARAGON DRUG DELIVERY SYSTEM
I-FLOW SIGNS NATIONAL DISTRIBUTION AGREEMENT FOR THE PARAGON WITH ONCOLOGY THERAPEUTICS NETWORK
I-FLOW SIGNS DISTRIBUTION AGREEMENT WITH FRESENIUS FOR DISTRIBUTION IN GERMANY, SWITZERLAND, AUSTRIA
I-FLOW CORP. OFFERS SYNOPSIS OF REMARKS AT CRUTTENDEN SOUTHERN CALIFORNIA GROWTH STOCK CONFERENCE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters